Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel for Seizure Control in Newly Diagnosed High Grade Glioma
NCT04497142Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2020
- Primary completion
- May 2023
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of perampanel in epilepsy, sponsored by Dana-Farber Cancer Institute. Started Nov 2020; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04497142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497142.